Reprieve Cardiovascular
Milford, US · Founded 2020 · Delaware corporation · 6 known investors
Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients. The technology gives physicians and care teams visibility and control over treatment to accelerate fluid removal while managing kidney injury risk, targeting hospital-based heart failure care in the U.S.
Founders & leadership
TF
Tony FieldsExecutive
AB
Adam BartnikExecutive
MP
Mark PacynainExecutive
JD
Jim DillonExecutive
HS
Hanson S. Gifford IIINamed on SEC filing
GW
Gregory W MannNamed on SEC filing
Board
Investors · 6
Arboretum VenturesAnn Arbor · $5M – $15Mvia Jan Garfinkle · board
Lightstone VenturesPortola Valleyvia Hanson S. Gifford · board
Rex Health VenturesRaleigh · $250K – $500K
Deerfield Management Companyreported · 2 sourcesNew Yorkvia Andrew ElBardissi · board
Genesis Venture CapitalreportedGrand Cayman
Sante VenturesreportedAustin · $2M – $6M
Reported raises · per SEC filings
Form D private placements$82.4M disclosed across 5 rounds · 2020–2025
▶$30.9MraisedJun 2025 · 12 investors · Other Health CareRule 506(b)
▶$30.9MraisedJun 2025 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jan GarfinkleDirector
- Tony FieldsExecutive Officer
- Mark PacynaExecutive Officer, Director
- Ethan BenovitzDirector
- James EadieDirector
- Hanson S. Gifford IIIDirector
- Adam BartnikExecutive Officer
- David NeustaedterDirector
- Offering amount
- $35.9M
- Amount sold
- $30.9M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$9.5MraisedJan 2025 · 8 investors · Other Health CareRule 506(b)
▶$9.5MraisedJan 2025 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James EadieDirector
- Tony FieldsExecutive Officer
- Adam BartnikExecutive Officer
- David NeustaedterDirector
- Ethan BenovitzDirector
- Mark PacynaExecutive Officer, Director
- Hanson S. Gifford IIIDirector
- Jan GarfinkleDirector
- Offering amount
- $10.5M
- Amount sold
- $9.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$12.1MraisedNov 2023 · 7 investors · Other Health CareRule 506(b)
▶$12.1MraisedNov 2023 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David NeustaedterDirector
- Gregory W. MannExecutive Officer
- Ethan BenovitzDirector
- Mark PacynaExecutive Officer, Director, Promoter
- Jan GarfinkleDirector
- Tony FieldsExecutive Officer
- James EadieDirector
- Hanson S. Gifford IIIDirector
- Offering amount
- $12.1M
- Amount sold
- $12.1M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedJun 2022 · 6 investors · Other Health CareRule 506(b)
▶$15MraisedJun 2022 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Hanson S. Gifford IIIDirector
- Andrew ElBardissiDirector
- Ethan BenovitzDirector
- Gregory W. MannExecutive Officer
- Mark PacynaExecutive Officer
- James EadieDirector
- Jim DillonExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedAug 2020 · 6 investors · Other Health CareRule 506(b)
▶$15MraisedAug 2020 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jim DillonExecutive Officer, Director
- James EadieDirector
- Ethan BenovitzDirector
- Hanson S Gifford IIIDirector
- Gregory W MannExecutive Officer
- Andrew ElBardissiDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Rf Surgical10 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Topera10 shared keywordsAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Aviary Health8 shared keywordsAviary Health provides virtual and hybrid clinical programs — including cardiac rehabilitation, pulmonary rehabilitation, and chronic care management — combining AI-powered workflows with clinical teams. It serves hospitals and health systems, delivering end-to-end support for complex service lines.
Companies competing with Reprieve Cardiovascular for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Reprieve Cardiovascular do?
- Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients. The technology gives physicians and care teams visibility and control over treatment to accelerate fluid removal while managing kidney injury risk, targeting hospital-based heart failure care in the U.S.
- Who are Reprieve Cardiovascular's investors?
- Reprieve Cardiovascular's investors include Arboretum Ventures, Lightstone Ventures, Rex Health Ventures, Deerfield Management Company, Genesis Venture Capital, Sante Ventures.
- How much funding has Reprieve Cardiovascular raised?
- Reprieve Cardiovascular has disclosed $82.4M raised across 5 rounds.
- Where is Reprieve Cardiovascular headquartered?
- Reprieve Cardiovascular is headquartered in Milford, US.